Tamsulosin

Generic Name: Tamsulosin

Brand Names: Flomax, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅S

CAS Number: 106133-20-4

Unique Ingredient Identifier: G3P28OML5I

Background: Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication: Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Associated Therapies: -

Clinical Trials

Prevention of Post-operative Urinary Retention

Phase 3

Completed

Conditions: Urinary Retention
Urinary Tract Infections

Interventions: Drug: Placebo
Drug: Tamsulosin

First Posted Date: 2015-07-01

Last Posted Date: 2019-09-25

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 158

Registration Number: NCT02486653

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population

Not Applicable

Conditions: Disorder of Urinary Stent

Interventions: Drug: Oxybutynin
Drug: Tamsulosin

First Posted Date: 2015-06-29

Last Posted Date: 2015-06-29

Lead Sponsor: Phoenix Children's Hospital

Target Recruit Count: 60

Registration Number: NCT02483793

Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression

Phase 4

Conditions: Bladder Cancer

Interventions: Drug: Tamsulosin
Procedure: Transurethral Resection

First Posted Date: 2015-05-14

Last Posted Date: 2015-05-14

Lead Sponsor: Diskapi Teaching and Research Hospital

Target Recruit Count: 40

Registration Number: NCT02443844

Locations: 🇹🇷
Turkish Ministry of Health Dıskapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey

Silodosin Versus Tamsulosin for Treatment of Ureteral Stones

Phase 4

Terminated

Conditions: Ureteral Stone
Ureteral Calculus
Ureterolithiasis

Interventions: Drug: Tamsulosin
Drug: Silodosin

First Posted Date: 2015-02-24

Last Posted Date: 2020-06-23

Lead Sponsor: Albert Einstein Healthcare Network

Target Recruit Count: 1

Registration Number: NCT02369744

Locations: 🇺🇸
Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States

Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.

Phase 4

Conditions: Overactive Bladder
Benign Prostatic Hyperplasia

Interventions: Drug: Mirabegron
Drug: Tamsulosin

First Posted Date: 2014-10-31

Last Posted Date: 2021-03-19

Lead Sponsor: St. Joseph's Healthcare Hamilton

Target Recruit Count: 200

Registration Number: NCT02279615

Locations: 🇨🇦
St. Joseph's Healthcare Hamilton - McMaster Institute of Urology, Hamilton, Ontario, Canada

Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Tamsulosin
Drug: Alfuzosin
Drug: Doxazosin

First Posted Date: 2014-10-17

Last Posted Date: 2014-10-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 97

Registration Number: NCT02266537

Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tamsulosin
Drug: Paroxetine

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02264184

Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: Tamsulosin

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 982

Registration Number: NCT02245529

Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia

Phase 4

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: Tamsulosin hydrochloride

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 493

Registration Number: NCT02244242

Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: Tamsulosin

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7391

Registration Number: NCT02245503

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy